Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C3H7NO3 |
| Molecular Weight | 105.0926 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CO)C(O)=O
InChI
InChIKey=MTCFGRXMJLQNBG-REOHCLBHSA-N
InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1
| Molecular Formula | C3H7NO3 |
| Molecular Weight | 105.0926 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12534373Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22045570 | https://www.ncbi.nlm.nih.gov/pubmed/27589995 | https://clinicaltrials.gov/ct2/show/NCT03062449
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12534373
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22045570 | https://www.ncbi.nlm.nih.gov/pubmed/27589995 | https://clinicaltrials.gov/ct2/show/NCT03062449
L-serineThe is a non-essential amino acid. L-serine and the products of its metabolism have been recognized not only to be essential for cell proliferation, but also to be necessary for specific functions in the central nervous system. The findings of altered levels of serine and glycine in patients with psychiatric disorders and the severe neurological abnormalities in patients with defects of L-serine synthesis underscore the importance of L-serine in brain development and function. L-serine supplementation is in trials for the treatment of several CNS diseases such as Alzheimer's disease, Hereditary sensory and autonomic neuropathy type 1 and Amyotrophic Lateral Sclerosis
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19963421
Curator's Comment: The de novo synthesis of the amino acid L-serine plays an essential role in the development and functioning of the central nervous system (CNS). L-serine displays many metabolic functions during different developmental stages; among its functions providing precursors for amino acids, protein synthesis, nucleotide synthesis, neurotransmitter synthesis and L-serine derived lipids. Patients with congenital defects in the L-serine synthesizing enzymes present with severe neurological abnormalities and underscore the importance of this synthetic pathway.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1250343 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22045570 |
|||
Target ID: CHEMBL1772927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12534373 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | FREAMINE III 10% Approved UseParenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is
indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric
patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or
should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal
absorption of protein is impaired; or (3) protein requirements are substantially increased as with
extensive burns. Dosage, route of administration, and concomitant infusion of non-protein
calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance Launch Date1971 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The ddcA gene from Streptomyces fradiae encodes an extracellular beta-lactamase with penicillinase and cephalosporinase activities. | 2001-11-30 |
|
| Nucleocytoplasmic shuttling of heterodimeric splicing factor U2AF. | 2001-04-20 |
|
| Differential regulation of the uridine nucleotide-activated P2Y4 and P2Y6 receptors. SER-333 and SER-334 in the carboxyl terminus are involved in agonist-dependent phosphorylation desensitization and internalization of the P2Y4 receptor. | 2001-04-13 |
|
| alpha 1-Proteinase inhibitor, alpha 1-antichymotrypsin, and alpha 2-macroglobulin are the antiapoptotic factors of vascular smooth muscle cells. | 2001-04-13 |
|
| Mutational and X-ray crystallographic analysis of the interaction of dihomo-gamma -linolenic acid with prostaglandin endoperoxide H synthases. | 2001-03-30 |
|
| Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. | 2001-03-30 |
|
| Phosphorylation of tau is regulated by PKN. | 2001-03-30 |
|
| Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. | 2001-03-23 |
|
| Polymerization of plasminogen activator inhibitor-1. | 2001-03-23 |
|
| Identification of the E2A gene products as regulatory targets of the G1 cyclin-dependent kinases. | 2001-03-16 |
|
| Structure and expression of the murine phosphatidylserine synthase-1 gene. | 2001-03-16 |
|
| The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. | 2001-03-09 |
|
| Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition. | 2001-03-09 |
|
| Characterization of phosphatidylserine transport to the locus of phosphatidylserine decarboxylase 2 in permeabilized yeast. | 2001-03-09 |
|
| Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling. | 2001-03-09 |
|
| Calpain mutants with increased Ca2+ sensitivity and implications for the role of the C(2)-like domain. | 2001-03-09 |
|
| Thermal denaturation of the Na,K-ATPase provides evidence for alpha-alpha oligomeric interaction and gamma subunit association with the C-terminal domain. | 2001-03-09 |
|
| Overexpression and characterization of carboxyl-terminal processing protease for precursor D1 protein: regulation of enzyme-substrate interaction by molecular environments. | 2001-03-09 |
|
| The fission yeast TOR homolog, tor1+, is required for the response to starvation and other stresses via a conserved serine. | 2001-03-09 |
|
| The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa. | 2001-03-09 |
|
| The two major plant plasma membrane H+-ATPases display different regulatory properties. | 2001-03-09 |
|
| Porphyromonas gingivalis DPP-7 represents a novel type of dipeptidylpeptidase. | 2001-03-02 |
|
| Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa. | 2001-03-02 |
|
| Elimination of phosphorylation sites of Semliki Forest virus replicase protein nsP3. | 2001-02-23 |
|
| Interaction of paxillin with p21-activated Kinase (PAK). Association of paxillin alpha with the kinase-inactive and the Cdc42-activated forms of PAK3. | 2001-02-23 |
|
| Probing the mechanism of inactivation of human pyruvate dehydrogenase by phosphorylation of three sites. | 2001-02-23 |
|
| Phosphorylation-induced change of the oligomerization state of alpha B-crystallin. | 2001-02-16 |
|
| The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner. | 2001-02-16 |
|
| Phosphatidylinositol 4-phosphate 5-kinase type I is regulated through phosphorylation response by extracellular stimuli. | 2001-02-16 |
|
| First isolation of human UDP-D-xylose: proteoglycan core protein beta-D-xylosyltransferase secreted from cultured JAR choriocarcinoma cells. | 2001-02-16 |
|
| Heterologous activation of protein kinase C stimulates phosphorylation of delta-opioid receptor at serine 344, resulting in beta-arrestin- and clathrin-mediated receptor internalization. | 2001-02-16 |
|
| Phosphorylation of the pro-apoptotic protein BIK: mapping of phosphorylation sites and effect on apoptosis. | 2001-02-16 |
|
| Myosin I phosphorylation is increased by chemotactic stimulation. | 2001-02-16 |
|
| The protease inhibitor, MG132, blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage by beta-Secretase. | 2001-02-09 |
|
| alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. | 2001-02-09 |
|
| Chloroplast RNA editing required for functional acetyl-CoA carboxylase in plants. | 2001-02-09 |
|
| Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. | 2001-02-09 |
|
| Model systems to assess the destructive potential of human neutrophils and monocyte-derived macrophages during the acute and chronic phases of inflammation. | 2001-02 |
|
| Alterations in the chain dynamics of insoluble elastin upon proteolysis by serine elastases. | 2001-02 |
|
| Characterization of the stromal protease(s) degrading the cross-linked products of the D1 protein generated by photoinhibition of photosystem II. | 2001-01-19 |
|
| Metabolism of glucagon by dipeptidyl peptidase IV (CD26). | 2001-01-12 |
|
| Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methyl-D-aspartate receptor-mediated synaptic transmission in mutant mice lacking D-amino-acid oxidase. | 2001-01-05 |
|
| Folding pathway mediated by an intramolecular chaperone: the structural and functional characterization of the aqualysin I propeptide. | 2001-01-05 |
|
| Increasing the thermal stability of euphauserase. A cold-active and multifunctional serine protease from Antarctic krill. | 2001-01 |
|
| Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis. | 2001-01 |
|
| Utilizing the peptidyl-prolyl cis-trans isomerase pin1 as a probe of its phosphorylated target proteins. Examples of binding to nuclear proteins in a human kidney cell line and to tau in Alzheimer's diseased brain. | 2001-01 |
|
| In vitro degradation of the Neb-Trypsin modulating oostatic factor (Neb-TMOF) in gut luminal content and hemolymph of the grey fleshfly, Neobellieria bullata. | 2001-01 |
|
| Towards the molecular basis of sperm and egg interaction during mammalian fertilization. | 2001 |
|
| cDNA expression cloning and characterization of phosphorylation dependent protein interactors using the yeast tribrid system. | 2001 |
|
| Identification of receptor tyrosine kinase associating proteins using the yeast two-hybrid system. | 2001 |
Sample Use Guides
Hereditary sensory and autonomic neuropathy type 1 (HSAN1) patients: 10-week oral l-serine 200 or 400 mg/kg body weight.
Amyotrophic Lateral Sclerosis patients: twice-daily dose regimens (0.5, 2.5, 7.5, or 15 g/dose).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22045570
Increasing L-serine medium concentrations (1-10 mM) substantially suppressed endogenous deoxysphinganine production in WT serine palmitoyltransferase SPTLC1 and hereditary sensory and autonomic neuropathy type 1 (HSAN1) mutant–expressing HEK293 cells
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:52:08 GMT 2025
by
admin
on
Mon Mar 31 17:52:08 GMT 2025
|
| Record UNII |
452VLY9402
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
2936-3
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
25523-2
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
22684-5
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
44403-4
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
47748-9
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
25979-6
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
32269-3
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
27223-7
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
47744-8
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
79601-1
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
NCI_THESAURUS |
C29596
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
2937-1
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
79645-8
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
15140-7
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
47747-1
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
22644-9
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
32270-1
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
2935-5
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
15136-5
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
47746-3
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
53395-0
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
13414-8
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
2938-9
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
47745-5
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
13808-1
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
17575-2
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
DSLD |
1687 (Number of products:408)
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
47743-0
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
56642-2
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
30058-2
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
47742-2
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
20656-5
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
25980-4
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
22741-3
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
79618-5
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
2934-8
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
LOINC |
26741-9
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
DSLD |
168 (Number of products:1)
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m9869
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | Merck Index | ||
|
33384
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
56-45-1
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
DTXSID60883230
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
1612506
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
680
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
17115
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
17822
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
SUB10494MIG
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
9671
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | RxNorm | ||
|
200-274-3
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
SERINE
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
452VLY9402
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
6170
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
5951
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
118365
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
D012694
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
CHEMBL11298
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
SUB21990
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
DB00133
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
100000084137
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
4127
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
452VLY9402
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
C29613
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY | |||
|
29999
Created by
admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|